Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Acoramidis hydrochloride (Alxn2060 hydrochloride) 是具有口服活性的、选择性的甲状腺素转运蛋白 (TTR (transthyretin)) 的稳定剂,对野生型和 V1221 突变型均有效。Acoramidis hydrochloride 可用于转体甲状腺素淀粉样变性的研究。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 995 | 现货 | ||
2 mg | ¥ 1,450 | 现货 | ||
5 mg | ¥ 2,390 | 现货 | ||
10 mg | ¥ 3,590 | 现货 | ||
25 mg | ¥ 6,250 | 现货 | ||
50 mg | ¥ 8,580 | 现货 | ||
100 mg | ¥ 11,500 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 2,630 | 现货 |
产品描述 | Acoramidis hydrochloride (Alxn2060 hydrochloride) is an orally active and selective kinetic stabilizer of WT and V122I- TTR (transthyretin) . Acoramidis hydrochloride is used in the study for transthyretin amyloidosis. |
体外活性 | Acoramidis (AG10, 0.1-10 μM for TTR ~5 μM) stabilizes V122I- and WT-TTR equally well and also exceeds their efficacy to stabilize WT and mutant TTR in whole serum [1] . Acoramidis (AG10) stimulates the mitochondrial QO2 in a concentration-dependent manner between 10 and 100 μM [3] . Acoramidis (AG10) has very minimal inhibition of two common off-targets in drug discovery, the potassium ion channel hERG (IC 50 > 100 μM) and a number of cytochrome P450 isozymes (IC 50 > 50 μM) (low toxicity) [1] . Western Blot Analysis [1] . Cell Line: Human serum (TTR ~5 μM). Concentration: 0.1 and 10 μM. Incubation Time: 72 h. Result: Was significantly more effective than tafamidis in stabilizing TTR. The concentration of AG10 to 10 μM resulted in stabilization of almost all of TTR in serum. |
体内活性 | Animal Model: Wistar rats [1] . Dosage: 50 mg/kg/d (Toxicity Analysis). Administration: Oral gavage, daily for 28 d. Result: Showed the plasma C max of ~40 μM and histopathological evaluation of liver, kidney, heart, spleen, thymus, and lung showed no signs of pathologic processes in the AG10-treated animals |
别名 | AG10 hydrochloride, Alxn2060 hydrochloride |
分子量 | 328.77 |
分子式 | C15H18ClFN2O3 |
CAS No. | 2242751-53-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 58.5 mg/mL (177.9 mM), Sonication is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 3.0416 mL | 15.2082 mL | 30.4164 mL | 76.041 mL |
5 mM | 0.6083 mL | 3.0416 mL | 6.0833 mL | 15.2082 mL | |
10 mM | 0.3042 mL | 1.5208 mL | 3.0416 mL | 7.6041 mL | |
20 mM | 0.1521 mL | 0.7604 mL | 1.5208 mL | 3.8021 mL | |
50 mM | 0.0608 mL | 0.3042 mL | 0.6083 mL | 1.5208 mL | |
100 mM | 0.0304 mL | 0.1521 mL | 0.3042 mL | 0.7604 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Acoramidis hydrochloride 2242751-53-5 Others Alxn2060 Hydrochloride AG10 hydrochloride AG-10 Hydrochloride AG10 Hydrochloride Alxn2060 hydrochloride AG 10 Hydrochloride Acoramidis Hydrochloride Inhibitor inhibitor inhibit